Soon-Shiong’s “Bioshield” Sparks Early Promise in Recurrent GBM, With 2 Near-CRs and 100% Disease Control
Patrick Soon-Shiong is back in the spotlight with early data from his Bioshield regimen in recurrent glioblastoma. The inventor of Abraxane and a transplant surgeon, Soon-Shiong says the approach could finally move the needle in one of oncology’s toughest indications.
In a series of posts on X, the ImmunityBio executive chairman called glioblastoma “medicine’s biggest challenge,” pointing to decades of limited progress with surgery, radiation and chemotherapy. Standard regimens, he noted, in 90% of cases deplete lymphocytes, crippling NK and T cells and leaving patients prone to relapse.
The new approach—described as a “chemo-free” combination of Bioshield, NK cell therapy plus an immune-stimulating device—aims to protect and rescue the immune system rather than destroy it.
So far, five patients with recurrent GBM have been treated. According to Soon-Shiong, two patients have achieved near-complete responses, while all five have shown 100% disease control. “When the immune system is protected, CR in tumors difficult to treat in recurrent GBM is possible,” he wrote.
Asked about the other three patients, Soon-Shiong said that one additional responder was seen early in the trial, and that the remaining two patients have just begun therapy and remain stable as they await follow-up MRIs.
The data are preliminary and based on five patients, but Soon-Shiong signaled that more readouts are on the way. ImmunityBio expects to present lung cancer data at the World Conference on Lung Cancer (WCLC25) next year.
The glioblastoma trial is open at CSSIFM.org
More posts featuring Pat Soon-Shiong.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023